細胞名稱

人甲狀腺癌細胞8505C

貨物編碼

BFN60808779

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研  2類

培養(yǎng)體系

DMEM高糖+10%FBS+1%三抗

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡介

人甲狀腺癌細胞8505C取自78歲女性供體。該細胞源于DSMZ。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: TCGA-110-CL cell line panel.

Doubling time: ~30-40 hours (DSMZ); 36 hours (ECACC).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Misspelling: 8509C; In Cosmic 1132598.

基因突變

Homozygous for BRAF p.Val600Glu (c.1799T>A) (PubMed=23833040; PubMed=30737244).

Homozygous for NF2 p.Glu129Ter (c.385G>T) (PubMed=30737244).

Heterozygous for TERT c.250C>T (-146C>T); in promoter (PubMed=23833040; PubMed=30737244).

Homozygous for TP53 p.Arg248Gly (c.742C>G) (PubMed=14522906; PubMed=23162534; PubMed=30737244).

HLA信息

/

STR信息

Amelogenin        X

CSF1PO        12,13

D2S1338        17,24

D3S1358        16,17

D5S818        10,11

D7S820        10

D8S1179        10,13

D13S317        13

D16S539        12

D18S51        16

D19S433        13,14

D21S11        28,32.2

FGA        23

Penta D        9,10

Penta E        12,15

TH01        6,9 (Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=21868764; PubMed=30737244; RCB; TKG)

6 (PubMed=25877200)

TPOX        10,11 (Cosmic-CLP; DSMZ; PubMed=30737244; RCB; TKG)

11 (ECACC; JCRB; PubMed=21868764; PubMed=25877200)

vWA        17,19

參考文獻

PubMed=22460905; DOI=10.1038/nature11003

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=23162534; DOI=10.3389/fendo.2012.00133

Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A., van Staveren W.C.G., Maenhaut C.

Thyroid cancer cell lines: an overview.

Front. Endocrinol. 3:133-133(2012)

PubMed=23833040; DOI=10.1210/jc.2013-2383

Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953

Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.

Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

Clin. Cancer Res. 25:3141-3151(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2

Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Nat. Commun. 10:3574-3574(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402(2020)